Get the Daily Brief
Latest Biotech News
Gilead accelerates ADC pipeline with Tubulis buyout
Gilead Sciences moved deeper into antibody-drug conjugates by agreeing to buy German ADC specialist Tubulis in a deal structured around a $3.15 billion upfront payment and up to $1.85 billion in...
Merck revises Terns offer after clinical data
Merck lowered its bid for Terns Pharmaceuticals after receiving new clinical-data signals, underscoring how ADC and oncology deals are increasingly sensitive to real-world efficacy and safety...
FDA pushes regulatory reforms to speed first-in-human trials
The U.S. FDA is proposing new pathways aimed at cutting time to first-in-human studies, using the 2027 budget to support more streamlined trial entry for sponsors with adequate preclinical...
AbbVie offers steep Humira discount via TrumpRx to avoid tariffs
AbbVie agreed to sell Humira through the government’s TrumpRx direct-to-consumer platform at a reported 86% discount as the administration works to manage tariff threats and broader pricing...
Novo Nordisk expands Wegovy to high-dose 7.2 mg
Novo Nordisk launched a higher-dose version of Wegovy in the U.S., adding a 7.2 mg injection to its chronic weight management regimen. The product expansion focuses on patients requiring step-up...
Neurocrine to acquire Soleno and bring Vykat into its rare-disease portfolio
Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion to obtain Vykat (diazoxide choline), its approved treatment for hyperphagia in Prader-Willi syndrome. Under the terms...
Sanofi’s lunsekimig posts respiratory wins but fails eczema Phase 2
Sanofi reported mixed Phase 2 outcomes for lunsekimig, a bispecific nanobody targeting TSLP and IL-13, succeeding in asthma and chronic rhinosinusitis with nasal polyps but failing to meet primary...
Digital health and diagnostics scale via cfDNA pregnancy test partnership
Zymo Research and Stori entered a collaboration to commercialize an at-home cfDNA-based early pregnancy test built on Zymo’s sample preservation and cfDNA extraction chemistries. The test is...
AI and single-cell tools support faster cell line development workflows
OneCyte and Kemp Proteins expanded bioprocess and discovery tooling by partnering to combine OneCyte’s high-throughput single-cell analysis for clone selection with Kemp’s PROTiQ machine-learning...
Private markets: Hologic deal closes after acquisition by Blackstone and TPG
Blackstone and TPG completed their acquisition of Hologic, taking the molecular diagnostics and women’s health company private in a transaction valued at up to $18.3 billion. Under the terms,...
Regulation: faster early clinical trial entry and domestic manufacturing incentives
The FDA is using the president’s 2027 budget proposal to outline new policies aimed at shortening the path to first-in-human studies and increasing U.S.-based drug development and manufacturing,...
M&A: Gilead’s $3.15B Tubulis deal strengthens ADC platform push
Gilead Sciences agreed to buy German biotech Tubulis for $3.15 billion upfront, with up to $1.85 billion more tied to milestones, in a deal focused on next-generation antibody-drug conjugates...
Immunology & drug development: Sanofi’s lunsekimig delivers mixed results across respiratory and eczema trials
Sanofi reported mixed Phase 2 data for lunsekimig, a bispecific nanobody targeting TSLP and IL-13, with the asset landing on efficacy in asthma and chronic rhinitis with nasal polyps but missing...
Regulatory and market access: FDA Fast Track for TRI-611 ALK-positive NSCLC molecular glue degrader
The FDA granted Fast Track designation to TRI-611 for ALK-positive non-small cell lung cancer, positioning the oral, brain-penetrant molecular glue degrader as a potential option after multiple...
M&A: Neurocrine to acquire Soleno for $2.9B to expand Prader-Willi medicine footprint
Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion, paying $53 per share in cash for the Prader-Willi syndrome asset Vykat (diazoxide choline), the companies said. The deal...
Diagnostics & liquid biopsy: UCLA’s methylation blood test aims for multi-disease detection
UCLA researchers published results for MethylScan, a low-cost, single-sample blood test that reads circulating cell-free DNA methylation patterns to detect multiple cancers and liver/organ...
Cancer genetics: Dutch team argues for routine whole-genome sequencing in cancer care
Researchers in the Netherlands are making the case for routine whole-genome sequencing (WGS) for cancer patients, arguing that broad testing yields a high rate of clinically actionable findings...
AI drug discovery: Ligand Pro’s Matcha virtual screening claims 30x speedups
Ligand Pro, founded by Skoltech professors and a Skoltech Ph.D. student, unveiled Matcha, an AI-powered molecular docking model designed to speed virtual drug screening. The company claims Matcha...
Cell therapy & platforms: TriNetX acquisition of Zetta Genomics assets to expand genomics analytics
TriNetX acquired Zetta Genomics assets, aiming to expand its genomics data management and analytics capabilities for healthcare providers and life science researchers. TriNetX’s platform already...
Funding & innovation: Syneron Bio raises $150M Series B for peptide development
Syneron Bio raised a $150 million Series B round to advance peptide therapeutics, according to company reporting, building on its prior $100 million round from the previous year. The company...